Mucosis Receives Financial Support from the Dutch Government for its SynGEM® Program

Groningen, the Netherlands, May 22, 2014 – Biotechnology com­pa­ny Mucosis B.V. today announced that it has received an inno­va­tion cred­it line of up to €5 mil­lion from the Netherlands Enterprise Agency, an agency of the Dutch Ministry of Economic Affairs.
Mucosis will use these funds to fur­ther advance the clin­i­cal devel­op­ment of its pro­pri­etary SynGEM® pre­fu­sion F RSV vac­cine can­di­date through human proof-of-con­cept stud­ies. These stud­ies aim to demon­strate both safe­ty and pro­tec­tion against a chal­lenge with RSV in healthy vol­un­teers.
“We are delight­ed to have the sup­port of the Dutch gov­ern­ment in such an impor­tant dis­ease area. Combined with our recent­ly announced strate­gic part­ner­ship with BCHT of China and new invest­ment round, we have now raised over €10 mil­lion in the first half of 2014. Advancing the SynGEM® pro­gram to human clin­i­cal tri­als through these funds will cre­ate a sub­stan­tial com­pa­ny val­ue inflec­tion point in the near term”, said Thomas Johnston, CEO of Mucosis. “Additionally, we see this sig­nif­i­cant fund­ing as a fur­ther val­i­da­tion of our clin­i­cal-stage Mimopath® plat­form and its poten­tial to com­bat the most chal­leng­ing of infec­tious dis­eases.”

Leave a Reply

Your email address will not be published. Required fields are marked *